Cargando…
Pharmacokinetics and safety of VALTOCO (NRL‐1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri‐ictal) and nonseizure (interictal) conditions: A phase 1, open‐label study
OBJECTIVE: To assess pharmacokinetics and safety of diazepam nasal spray (NRL‐1; VALTOCO®) in pediatric and adult patients with epilepsy in seizure and nonseizure states. METHODS: A single dose of diazepam nasal spray (5, 10, 15, or 20 mg based on weight) was administered during each of two conditio...
Autores principales: | Hogan, Robert Edward, Tarquinio, Daniel, Sperling, Michael R., Klein, Pavel, Miller, Ian, Segal, Eric B., Rabinowicz, Adrian L., Carrazana, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383779/ https://www.ncbi.nlm.nih.gov/pubmed/32338380 http://dx.doi.org/10.1111/epi.16506 |
Ejemplares similares
-
Consistent safety and tolerability of Valtoco(®) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study
por: Miller, Ian, et al.
Publicado: (2021) -
Ictal and Peri-Ictal Psychopathology
por: Mula, Marco, et al.
Publicado: (2011) -
Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out‐of‐hospital seizure clusters: Results from a phase 3, open‐label, repeat‐dose safety study
por: Sperling, Michael R., et al.
Publicado: (2022) -
Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
por: Wheless, James W., et al.
Publicado: (2021) -
VALTOCO(®) (Diazepam Nasal Spray) for the Acute Treatment of Intermittent Stereotypic Episodes of Frequent Seizure Activity
por: Cornett, Elyse M., et al.
Publicado: (2021)